Drug Profile
Doxorubicin liposomal - ALZA
Alternative Names: Caelyx; Dox-SL; Doxil; JNS-002; Liposomal doxorubicin - ALZA; Pegylated liposomal doxorubicin; SPI 49Latest Information Update: 18 Dec 2021
Price :
$50
*
At a glance
- Originator ALZA Corporation
- Developer Janssen Biotech; University of Kansas Medical Center; Xian-Janssen
- Class Anthracyclines; Antineoplastics; Antivirals; Cytostatic antibiotics; Doxorubicins; Hepatoprotectants; Small molecules
- Mechanism of Action Reactive oxygen species stimulants; RNA synthesis inhibitors; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Breast cancer; Kaposi's sarcoma; Multiple myeloma; Ovarian cancer
Most Recent Events
- 14 Sep 2020 No development reported - Phase-II for Multiple myeloma (Combination therapy, First-line therapy, In the elderly, Newly diagnosed, In adults) in USA (IV)
- 01 Sep 2016 Schering-Plough in collaboration with SOLTI Breast Cancer Research Group completes a phase II trial for Breast cancer in Spain (NCT00563953)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Multiple-myeloma(Combination therapy, Second-line therapy or greater) in Japan (IV)